While Amgen and Ortho Biotech tried to put a positive spin on Tuesday's votes by a federal advisory panel about anemia drugs, the outcome of the meeting is not as benign as it appeared for the future of the drugs, predicted Lazard Capital Markets analyst Joel Sendek. (BioWorld Today)